Detection of cardiotoxic hazards

Area of Science:

• Cardiovascular toxicology
• Drug safety evaluation
• Mitochondrial function

Background:

• Routine toxicity tests often lack sufficient sensitivity for early cardiovascular toxicity detection.
• Morphological and biochemical assessments may not fully capture functional or metabolic cardiotoxic effects.
• Assessing drug interactions requires sensitive methods for cardiovascular risk.

Purpose of the Study:

• To highlight the necessity of functional and metabolic measurements for comprehensive cardiovascular toxicity assessment.
• To demonstrate the efficacy of specific techniques in early cardiotoxic effect detection.
• To evaluate methods for assessing cardiotoxic hazards of pharmaceutical agents.

Main Methods:

• Utilized blood pressure and electrocardiogram (ECG) monitoring for detecting cardiotoxicity.
• Employed mitochondrial function measurements to assess metabolic hazards.
• Applied these methods to evaluate known cardiotoxic agents (allylamine, emetine) and a hypoglycemic agent (MTG).

Main Results:

• Early detection of cardiotoxic effects from allylamine and emetine was achieved using blood pressure and ECG monitoring.
• These functional monitoring techniques proved effective in assessing potential drug interactions.
• Measurement of mitochondrial function was the most effective method for demonstrating the cardiotoxic hazard of the hypoglycemic agent MTG.

Conclusions:

• Functional and metabolic assessments are essential supplements to routine toxicity testing for cardiovascular safety.
• Blood pressure and ECG monitoring offer early detection of cardiotoxicity and aid in drug interaction assessment.
• Mitochondrial function assays are critical for identifying metabolic cardiotoxic hazards, particularly for agents like MTG.